



M.M.

OBO

Recip

H
B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Pascale Pouzet et al
Serial No. : 10/058,456
Filed : January 28, 2002
For : Alkylphenyliminoimidazolidine Derivatives for Treating Urinary
Incontinence

Docket No.: 1/1168
) Art Unit: to be assigned
) Examiner: to be assigned

Office of Initial Patent Examination's
Customer Service Center
Assistant Commissioner for Patents
Washington, DC 20231

REQUEST FOR CORRECTION OF FILING RECEIPT

Sir:

The undersigned respectfully requests correction of the Filing Receipt for
Application Number 10/058,456.

Please correct the resident city of the sixth named inventor (Ikunobu
Muramatsu) from "Yoshida-gun" to --Hyogo--, as noted on the attached copy of the
Official Filing Receipt.

The undersigned hereby requests that the United States Patent and Trademark
Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Timothy X. Witkowski
Registration No. 40,232

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4310
Date: March 14, 2002
Docket No.: 1/1168



UNITED STATES PATENT AND TRADEMARK OFFICE

d TXW
Page 1 of 2

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/058,456	01/28/2002	1614	920	1/1168		30	3

CONFIRMATION NO. 4239

28501
BOEHRINGER INGELHEIM CORPORATION
900 RIDGEBURY ROAD
P. O. BOX 368
RIDGEFIELD, CT 06877

FILING RECEIPT




OC00000007532429

Date Mailed: 02/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Pascale Pouzet, Biberach, GERMANY;
Franz Esser, Ingelheim, GERMANY;
Matthias Hoffmann, Mittelbiberach, GERMANY;
Hisato Kitagawa, Osaka, JAPAN;
Kenji Sakai, Hyogo, JAPAN;
Ikunobu Muramatsu, ~~Yoshida-gu~~, JAPAN;
Hyogo



Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/270,333 02/21/2001

Foreign Applications

GERMANY 101 06 214.1 02/10/2001

If Required, Foreign Filing License Granted 02/25/2002


Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

Title

Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence



Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).